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Various patient reported outcome measures (PROMs) are used in idiopathic pulmonary 
fibrosis (IPF). We aimed to describe their psychometric properties, assess their 
relationship with 1-year mortality and determine their minimal clinically important 
differences (MCID).  
 
Methods 
In a prospective multicentre study, participants with IPF completed the King’s Brief 
Interstitial Lung Disease Questionnaire (K-BILD), the modified Medical Research 
Council (mMRC) dyspnoea scale, St George’s Respiratory Questionnaire (SGRQ) and 
University of California, San Diego shortness of breath questionnaire (UCSD-SOBQ) 
three-monthly intervals over a 12-month period. Forced vital capacity (FVC) was 
matched with questionnaires and mortality was captured. Anchor- and distribution-
based methods were used to derive MCID. 
 
Results 
Data were available from 238 participants. All PROMs had good internal consistency 
and high degree of correlations with other tools (except UCSD-SOBQ correlated poorly 
with FVC). There were significant associations with mortality for K-BILD (hazard ratio 
16.67; 95% CI 2.38-100) and SGRQ (hazard ratio 4.65; 95% CI 1.32-16.62) but not with 
the other PROMs or FVC. The median MCID (range) for K-BILD was 6.3 (4.1- 7.0), 
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The K-BILD was related to other severity measures and had the strongest relationship 
with mortality.  
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Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease with 
significant morbidity and mortality1. Assessing patient reported outcome measures 
(PROMs), including assessments of breathlessness and health-related quality of life 
(HRQOL), in people with IPF is important as they are outcomes of clinical trials2 and 
part of clinical service specifications (www.nice.org.uk/CG163). However, as no 
universally accepted tool exists, different patient PROMs used. 
 
The St George’s Respiratory Questionnaire (SGRQ)3 and King’s Brief Interstitial Lung 
disease questionnaire (K-BILD)4 are the most commonly employed tools in IPF. 
However, the SGRQ was developed for use in people with chronic obstructive 
pulmonary disease (COPD), for which its minimal important clinical difference (MCID) is 
between 7 and 105, and although it relates to physiological impairment in IPF, an IPF-
specific version (SGRQ-I) has been developed and validated6. In terms of assessing 
breathlessness in IPF, the University of California, San Diego shortness of breath 
questionnaire (UCSD-SOBQ)7, and the modified Medicine Research Council (mMRC) 
dyspnoea scale8 are the most frequently used, both of which were also developed 
mostly in patients with COPD. The EuroQol 5 dimension 5 level (EQ-5D-5L) is a well-
validated global health status instrument designed for use in clinical and health-
economic trials9. Anxiety and depression is common in IPF and related to HRQOL10; it 




Assessment of the psychometric properties of PROMs in people with IPF is important to 
understand their suitability for use in clinical research and practice. The psychometric 
properties of SGRQ in people with IPF have been reviewed11 and recently evaluated 
from data from trials of nintedanib12, 13. Likewise the validation of K-BILD14 and SGRQ-
I15 have also been evaluated separately in a Danish cohort of 150 people with IPF.  
However, neither the HADS nor the mMRC have been validated in IPF.  Our aim, in this 
large prospective multicentre UK-wide study, was to describe the internal consistency, 
construct validity and known group validity of the SGRQ, K-BILD, mMRC dyspnoea 
score, UCSD-SOBQ, HADS and EQ-5D-5L simultaneously so that their qualities can be 
contrasted. We aimed to determine their MCID and relationship to 1-year mortality. 
 
METHODS 
This was an observational prospective longitudinal multicentre study, of seven 
Specialist Interstitial Lung disease (ILD) centres throughout the UK (Bristol, Cambridge, 
Devon & Exeter, Newcastle, North Staffordshire, Norwich, Sheffield) over 12 months. 
Participants were identified by clinical staff and recruited by local researchers who 
administered the questionnaires. The questionnaires were self-completed unsupervised 
either in hospital reception rooms or at home. Data were collected between July 2014 
and October 2016. The study was conducted according to the principles of Good 
Clinical Practice. It was approved by NRES Committee South West– Exeter (Reference 






Participants were identified by reviewing hospital databases, patient registries and 
medical notes. Participants were eligible for enrolment if they were aged more than 40 
years and had IPF based on multi-disciplinary consensus, according to 
contemporaneous guidelines16, and were able to provide written informed consent. 
Participants were excluded if they had a significant co-existing respiratory disease, 
medical or psychiatric condition exhibiting a clinically relevant effect on symptoms, 
HRQOL and disease progression as determined by the principal investigator. 
Participants with airflow obstruction defined as a ratio of forced expiratory volume in 1 
second (FEV1) to forced vital volume (FVC) of less than 0.6 or a residual volume greater 
than 120% predicted were also excluded2, 17.  
 
Outcome measures 
The following PROMs were presented in the order below, but the order of completion 
was not monitored. EQ-5D-5L9 contains five dimensions: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. Each dimension is answered on a 
five-level scale (1 no problems, 5 severe problems/unable to do). It was converted to 
utilities using standard UK health state valuations. K-BILD4 describes health status 
during the past two weeks in people with ILD. It contains 15 questions evaluating three 
dimensions; psychological, breathlessness and activity, and chest symptoms on a 
seven-point Likert scale. Total score ranges from 0 (worst health status) to 100 (best 
health status). SGRQ3 incorporates 50 items across three domains: symptoms, activity 
and impacts. The total score ranges from 0 (best health status) to 100 (worst health 
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status). The SGRQ-I was generated from the SGRQ data. The mMRC8 is commonly 
used to assess breathlessness and response is classified into the 5 point scale (0 
dyspnoea with strenuous exercise, 4 too breathless to leave house or breathless when 
dressing). The UCSD-SOBQ7 is a domain-specific tool assessing breathlessness 
associated with activities of daily livings. It includes 24 questions, rating answers on a 0 
(not at all breathless) to 5 (maximally breathless). The total scores range from 0 (lesser 
dyspnoea) to 120 (greater dyspnoea). HADS18 contains seven questions for anxiety and 
seven questions for depression. Scores can be added to measure psychological 
distress. Patient Global Impression of Change (PGIC) is used to quantify perceived 
changes in health status over time scale. We used a 15-point scale in this study19. 
 
Spirometry20 and a six-minute walk test (6MWT)21 was performed unless undertaken for 
clinical reasons within the preceding four weeks. Additional physiological data were 
obtained from the medical notes, including static lung volumes and total lung diffusing 
capacity of carbon monoxide (DLCO), if these had been conducted as part of routine 
care within four weeks of questionnaire completion.  
 
The visit schedule was aligned to routine care with follow-up measurements (PROMs 
and spirometry) collected approximately every three months. Participants unable or 
unwilling to attend for clinic visits were mailed the questionnaires after ensuring their 
vital status. Questionnaires were matched if they were completed within 14 days of 
each other. They were also matched with physiological data if they were within 28 days 
of each other. Questionnaires with no reliable date were not included in the analysis. 
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Mortality data were obtained from serious adverse event logs. Deaths were verified by 
the principal investigator at each site and vital status was checked prior to mailing 
PROMs but was not cross referenced to Office of National Statistics (ONS) data. 
 
Data from all PROMs were captured even if the return date was not at 3-monthly 
intervals. All PROMs were electronically scanned using formic optical character 
recognition software (Formic Limited, Middlesex, Uxbridge, UK) and scored by the 
research team and analysed by the study statistician (AC). 
 
Statistical analysis 
A sample size of 200 has 99% power to detect a correlation of 0.3 at 5% significance for 
the convergent validity analysis and a sample size of 150 provides 86% power to detect 




Internal consistency was assessed using the Cronbach’s α coefficient at baseline, the 
confidence interval was estimated based on a bootstrap with 500 replications. We 
considered a value greater than 0.7 is considered to represent a homogenous scale22. 
 
Convergent validity 
Convergent validity was evaluated by assessing the correlation between the different 
HQROL and breathlessness tools and physiological measurements including FVC % 
predicted and 6-minute walk distance (6MWD) using Spearman correlation coefficients. 
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Correlations were considered as weak if < 0.30, moderate, 0.3-0.6 and strong >0.60. 
We hypothesised that the correlation between K-BILD and SGRQ would be strong4 and 
between K-BILD and FVC would be weak23. We expected there to be inverse 
relationships between PROMs with opposite directions and that low FVC related 
positively to poor health states identified by the PROMs. 
 
Known-group validity 
Known group validity was assessed by measuring the difference between the values, 
using a two sample t-test, for the first measurement obtained from people with FVC > 
75% and values from people with FVC ≤ 75% i.e. only one measurement was obtained 
for each person24.  
 
Relationship with 1-year mortality  
The Kaplan-Meier curve was used to describe the survival time. A tertile analysis was 
undertaken to describe relationship between 1-year mortality and each PROM tool. 
Individuals were divided into three equal groups according to the baseline total score of 
each questionnaire: group 1 (better health status), group 2, and group 3 (worse health 
status). A comparison of survival between tertile groups was made. Cox’s proportional 
hazards model was used to estimate the hazard ratio for each variable separately with 
no adjustment for potential confounding factors. Analysis were repeated using FVC % 
predicted. Patients were divided into two groups based on lung function (FVC> 75% or 




Minimal clinically important difference  
Anchor-based method was used to derive MCID of the PROMs25. To detect MCID within 
patients (longitudinal), patients were stratified into two groups based on difference in 
PGIC from the first visit to the second visit26. Data were restricted to those patients with 
visits less than 100 days apart. Participants were considered as unchanged if (-1, 0, 1) 
and minimally changed if (-2 and -3). Distribution-based methods were also used to 
derive estimates of the MCID. The standard error of measurement (SEM) method was 
used. The intraclass correlation coefficient for this method was estimated using data 
from participants who reported that their health did not change between visits. The 0.5 x 





Two hundred and fifty participants were enrolled into this study and data were available 
from 238 individuals. (Table 1) The median time between visits was 98 days (ranged 
from 16 to 447 days). There was a total of 778 evaluable EQ-5D-5L questionnaires with 
each individual having an average of 3.3 questionnaires. There was greater variation 
between individuals than within individuals for change over 12 months i.e. participants’ 
outcome measures were relatively static over the 12-month period. (Table 2) There was 






All questionnaires showed good internal consistency with Cronbach’s alpha coefficients 
of > 0.8. The Cronbach’s alpha and 95% CI were EQ-5D: 0.86 (0.84, 0.87), HADS: 0.91 
(0.90, 0.92), K-BILD: 0.95 (0.94, 0.95), SGRQ: 0.94 (0.93, 0.94) and UCSD-SOBQ: 0.98 
(0.97, 0.98).  
 
Convergent validity 
The correlations between questionnaires were mostly strong. (Table 3) The mMRC 
dyspnoea scale showed moderate correlations with FVC % predicted and 6MWD. 
SGRQ, SGRQ-I and K-BILD had a moderate correlation with FVC% predicted but a 
weak correlation with 6MWD. Correlation between UCSD-SOBQ and 6MWD was 
moderate, but correlation between UCSD-SOBQ and FVC % predicted was weak. EQ-
5D and HADS showed weak correlations with both FVC % and 6MWD. (Table 3) 
 
Known-group validity  
People with FVC % predicted ≤ 75% had higher mean SGRQ, mMRC and UCSD-
SOBQ scores, and lower mean EQ-5D and K-BILD score. There was no statistically 
significant difference in mean HADS scores between the groups. (Table 4) 
 
Relationship to 1-year mortality  
There was a total of 26 (10.9%) deaths. The correlation between PGIC and PROMs 
were weak (r= 0.05 – 0.37). K-BILD showed a strong association with 1-year mortality. 
People with worse health status (in the lower tertile) had significantly increased risk of 
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deaths than those with best health status (upper tertile) for K-BILD (HR 16.67; 95% CI 
2.38 – 100), SGRQ (HR 4.65; 95% CI 1.32-16.62), EQ-5D-5L (HR 3.70; 95% CI 1.23 – 
11.11) but not for MRC (HR 1.72; 95% CI 0.58 – 5.12), HADS (HR 3.11; 95% CI 0.82 – 
11.71), UCSD-SOBQ (HR 1.78; 95% CI 0.58 – 5.43) or SGRQ-I (HR 3.19; 95% CI 1.03 
– 9.89). (Figure 1) There was no difference between the survival of those with an FVC 
higher or lower/equal to 75% predicted (HR 1.67; 95% CI 0.68 – 4.1). 
 
Minimal important clinical difference  
Eighty-seven participants were considered unchanged from visit 1 to visit 2 and 36 




Summary of main findings 
This the first study to report the psychometric properties, MCID and relationship with 
mortality of seven commonly used PROMs concurrently. We have shown that all 
questionnaires investigated in this study had good internal consistency and high degree 
of correlations with other tools, consistent with good convergent validity. However, the 
convergent validity between FVC and 6-minute walk distance and the PROMs were 
poor suggesting that physiological measurements only capture a small component of 
HRQOL or breathlessness. The SGRQ, SGRQ-I, EQ-5D-5L, mMRC, UCSD and K-BILD 
were able to discriminate individuals according to accepted physiological measure of 
disease severity in contrast to HADS suggesting that these reflect disease severity 
better. K-BILD, EQ-5D-5L, SGRQ, and SGRQ-I were associated with mortality at 1 year 
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whereas mMRC, HADS, UCSD and FVC % predicted ≤ 75% were not. This suggests 
HRQOL is a major determinant of outcome; the multiple domains capture aspects of 
disease severity better than breathlessness or physiology alone. The median MCID 
(range) for K-BILD was 6.3 (4.1- 7.0), SGRQ was 7.0 (3.8 - 9.6), mMRC was 0.4 (0.1-
0.5), UCSD was 9.6 (4.1 - 14.2) and HADS 2.4 (0.9 – 3.7).  
 
Strengths and limitations 
This was a prospective longitudinal study recruiting 250 patients of varying in disease 
severity. We used a multicentre approach and wide entry criteria to reflect real world 
population. As a result, comorbidities were common in our population with half of 
patients having at least one comorbidity at a rate similar to the German registry27. We 
have not considered comorbidities and change in health status may have been due to 
factors, such as pulmonary rehabilitation or oxygen therapy that was not captured in our 
study. However, including individuals with comorbidities increases the generalisability of 
our findings.  
 
Participants’ outcome measures were relatively static during study period and there was 
only a small number of individuals showed minimal change in PGIC (n=36). We 
employed both anchor and distribution-based methods as is recommended28. There 
was a large difference between the distribution based MCIDs and the anchor based 
MCIDs with the distribution-based methods giving significantly larger values, especially 
the 0.5 standard deviation (SD). However, 0.5 SD represents medium effect size29, 
giving greater values than the minimally important difference. For the standard error 
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measurement (SEM) approach, we used threshold of 1 SEM which is the traditionally 
used value in assessing MCID28.  
 
The main limitation of this study is that there was large amount of missing data 
especially for the spirometry and 6MWT as many individuals agreed to complete the 
questionnaires as they were mailed to their home but declined to attend hospital for 
physiological tests. Furthermore, many participants did not complete questionnaires at 
pre-specified time intervals. We could not use supplemental oxygen status or DLCO % 
predicted in our analysis due to small number of patients receiving oxygen and small 
number of DLCO measurements. Additionally, only a small proportion of deaths 
occurred in our study population, which were not cross-referenced to National 
databases. Therefore, a careful approach needs to be taken when interpreting our 
results and further study on the roles of PROMs in survival prediction is required. We 
might have achieved a stronger correlation between the physiological measurements 
and questionnaire data had we limited the analysis to a relevant questionnaire domain 
such as the activity domain of the SGRQ. The PGIC asked about change since the 
preceding visit and therefore we were only able to report the MCID over a short 
timescale; there would have been more people with a change over a 1-year period but 
there would have been more patient withdrawals and recall basis. The correlation 
between the PGIC and most of the PROMs assessed were weak and less the 
recommended correlation coefficient >0.3 for determining MCIDs. Future studies should 
consider using alternative anchors such as the Patient Global Impression of Severity 
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scale, which assesses severity of the condition in real time, as it is not susceptible to 
patients having to recall their previous health states. 
 
This study was conducted shortly after National Institute for Health and Care Excellence 
(NICE) approval for pirfenidone and nintedanib, therefore, few people were receiving 
these treatments and we did not undertake subgroup analysis with those receiving anti-
fibrotic therapy. Post hoc analysis of data from the INPULSIS trials showed that 
nintedanib treatment resulted in a less decline in PROMs than placebo treated group30. 
It is likely therefore that changes in PROMs will be different if patients are receiving anti-
fibrotic medication. 
 
Comparison with existing literature 
The findings of our study are in keeping with a Danish IPF study which reported high 
internal consistency, good reliability and strong concurrent validity of the K-BILD14 and 
the SGRQ-I15. The MCID of SGRQ reported here (4-10) was similar to that of people 
with COPD (7-10)5, 31 and connective tissue related ILD (4-13)24 and the MCID of K-
BILD (4-7) was similar to that of with ILD (4-7)32 and IPF(3-5)33. The Danish team34, 
analysed the MCID for improvement separately from deterioration (SGRQ-I Total (4 and 
5) and K-BILD Total (5 and 3)) suggesting that people perceive improvement and 
deterioration differently. 
 
Other studies have supported the use of PROM in predicting mortality in IPF. The data 
from IPF-PRO Registry showed that worse health status on the SGRQ total score were 
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associated with mortality or lung transplant over 1 year with stronger relationship than 
FVC% predicted35. The relationship between K-BILD and survival prediction in ILD has 
been previously explored and reported K-BILD total score of > 34 was associated with 
longer estimated median survival (36.4 months) than K-BILD <34 (9.7 month, p 
=0.02)36. 
  
We did not find the UCSD-SOBQ to be associated with mortality at 1-year. However, 
recent study of the German registry27 demonstrated greater change in UCSD-SOBQ 
scores from baseline (20.4 ± 1.5) in patients who died (n=113) compared with survivors 
(7.0 ± 29.1). The HADS showed weak correlations with physiological measurements, 
which is not surprising as HADS aims to measure psychological distress. However, 
moderate to strong correlations between HADS and PROMs were observed, suggesting 
association between depression and anxiety and HRQOL. Our findings are supported 
by previous studies of people with ILD that reported associations between depression 
and UCSD-SOBQ 37 and mMRC38. However, depression (defined as HADS-D ≥ 8) and 
anxiety (defined as HADS-A ≥ 8) were not associated with survival rate or hospital 
admission rate39.   
 
Implications for future research or clinical practice 
All the questionnaires used are related but capture different aspects of the disease. In 
clinical setting, mMRC dyspnoea scale rather than UCSD-SOBQ could be employed to 
assess breathlessness given its brevity and greater relationship to other measures of 
disease severity. Both the K-BILD and SGRQ were appropriate tools for evaluating 
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HRQOL. In clinical setting, K-BILD might be more appropriate given its stronger 
relationship to mortality and its brevity. The SGRQ-I was not superior to the SGRQ in 
our study. Further studies should consider examining the psychometric properties of 
each domain to guide researchers to select PROMs most suitable to their needs.  
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Figure 1 Survival curves for Patient Related Outcome Measures 
 
 
Kaplan-Meier curves for survival (1-year mortality) for (a) SGRQ: St George’s Respiratory Questionnaire 
(b) EQ5D: 5-Level Euroqol 5-dimension (c) mMRC: modified Medical Research Council dyspnoea scale 
(d) HADS: Hospital Anxiety and Depression Score (e) K-BILD: King’s Brief Interstitial Lung Disease 
Questionnaire, (f) UCSD-SOBQ: University of California, San Diego shortness of breath questionnaire. 
Individuals were divided into three equal groups according to the baseline total score of each 
questionnaire: better, middle, worse health status. A comparison was made between tertile groups. Solid 
lines represent the better health status, dashed lines represent middle health status, and dotted lines 






Table 1 Characteristics of participants (n=238) 
Characteristic  N Mean (SD) 
Male sex  171 (71.8) 
 
Age, years  231 72. 6 (7.6) 
BMI, kg/m2  207 27.7 (4.0) 
Caucasian   205 (98.1) 
 
Disease duration, years  194 3.19 (2.8) 
Smoking status  211 
 
Never  52 (26.5) 
 
Former  150 (71.1) 
 










Emphysema   29 (12.2) 
 
GORD  88 (37.0) 
 
Hypertension  79 (33.2) 
 
IHD  52 (51.8) 
 
Pulmonary hypertension  13 (5.5) 
 
COPD  10 (4.2) 
 
Pirfenidone  79 (33.2) 
 
Nintedanib  7 (2.9) 
 
N-Acetylcystein  15 (6.3) 
 
Prednisolone  17 (7.1) 
 
Home oxygen  49 (20.6) 
 
FVC (% predicted)  77.68 (17.34) 
FEV1 (% predicted)  82.18 (18.28) 
DLCO (% predicted)  47.75 (14.97) 
 
The mean and standard deviation or percentage for the demographic variables. BMI: body mass index, 
COPD: chronic obstructive pulmonary disease, GORD: gastroesophageal reflux disease, HRCT: high 





Table 2 Descriptive statistics of variables observed over 12 months 
 First Visit Second visit 
 N Mean (SD) N Mean (SD) 
SGRQ 226 42.64 (19.15) 195 44.64 (19.34) 
K-BILD 224 55.71 (14.02) 191 55.59 (13.67) 
mMRC  215 2.71 (1.05) 190 2.72 (1.05) 
HADS total 220 10.68 (7.36) 185 10.99 (7.38) 
UCSD-SOBQ 188 38.29 (28.38) 147 39.89 (28.02) 
EQ-5D  238 0.69 (0.22) 200 0.68 (0.24) 
SGRQ-I 226 43.58 (22.49) 195 45.50 (22.98) 
FVC (%) 165 77.68 (7.34) 104 77.67 (17.32) 
FEV1 (%) 163 82.18 (18.28) 104 81.52 (17.20) 
6MWD 116 329.66 (138.02) 104 330.51 (139.32) 
  
SGRQ: St George’s Respiratory Questionnaire, K-BILD: King’s brief interstitial lung disease 
questionnaire, mMRC: Medical Research Council dyspnea score, HADS: Hospital anxiety and depression 
scale, UCSD-SOB: University of California, San Diego shortness of breath questionnaire, EQ-5D-5L: 
EuroQol 5 Dimension 5 Level, SGRQ-I: St George’s Respiratory Questionnaire – Interstitial lung disease, 







Table 3 Convergent validity 
 
 
Correlation coefficients for EQ-5D-5L: EQ-5D: EuroQol 5 Dimension, FVC: forced vital capacity, HADS: 
Hospital anxiety and depression scale, K-BILD: King’s brief interstitial lung disease questionnaire, mMRC: 
Medical Research Council dyspnea score, SGRQ: St George’s Respiratory Questionnaire, SGRQ-I, St 
George’s Respiratory Questionnaire – Interstitial lung disease, UCSD: University of California, San Diego 
shortness of breath questionnaire, 6MWD: 6 minute walk test distance. Correlations were considered as 
weak if < 0.30, moderate, 0.3-0.6 and strong >0.60 
  
Measure SGRQ EQ-5D MRC HADS K-BILD UCSD SGRQ-I FVC % 
pred 
6MWD 
SGRQ 1 -0.74 0.68 0.67 -0.84 0.83 0.97 -0.36 -0.29 
EQ-5D  1 -0.60 -0.66 0.73 -0.78 -0.74 0.34 0.28 
MRC   1 0.49 -0.63 0.74 0.67 -0.35 -0.38 
HADS    1 -0.74 0.60 0.64 -0.13 -0.15 
K-BILD     1 -0.74 -0.81 0.33 0.25 
UCSD      1 0.822 -0.28 -0.34 
SGRQ-I       1 -0.34 -0.29 
FVC % pred        1 - 
6MWD         1 
25 
 
Table 4 Known group validity 




Mean difference (95% CI) p-value 
SGRQ 37.82 (18.13) 46.68 (18.16) 8.86 (3.20,14.53) 0.002 
EQ-5D 0.74 (0.18) 0.64 (0.22) -0.10 (-0.16,-0.03) 0.003 
MRC 2.38 (1.03) 2.93 (0.87) 0.55 (0.24,0.86) <0.001 
HADS 9.83 (7.90) 11.41 (6.50) 1.58 (-0.75,3.91) 0.18 
K-BILD 58.87 (14.31) 52.19 (12.21) -6.68 (-10.94,-2.41) 0.002 
UCSD 31.41 (25.07) 41.02 (26.28) 9.61 (0.81,18.42) 0.033 
SGRQ-I 39.16 (21.84) 47.37 (21.35) 8.21 (1.46,14.96) 0.017 
 
A comparison between those with an Forced vital capacity (FVC) greater than or equal or less than 75% 
predicted for EQ-5D-5L: EQ-5D: EuroQol 5 Dimension, HADS: Hospital anxiety and depression scale, K-
BILD: King’s brief interstitial lung disease questionnaire, mMRC: Medical Research Council dyspnea 
score, SGRQ: St George’s Respiratory Questionnaire, SGRQ-I, St George’s Respiratory Questionnaire – 
Interstitial lung disease, UCSD-SOBQ: University of California, San Diego shortness of breath 
questionnaire. All questionnaires other than UCSD-SOBQ were able to distinguish between subgroups. 





 Table 5 The within patient minimal clinically important difference  
 
Anchor-based method 
MCID (95% CI) 
Distribution-based methods Median 
0.5 x SD (95% CI) 1 x SEM (95% CI) 
SGRQ 3.84 (-3.24,10.94) 9.58 (8.9,10.39) 6.96 (3.23,3.77) 6.96 
EQ-5D 0.06 (-0.01, 0.13) 0.11 (0.1,0.12) 0.11 (0.05,0.06) 0.11 
MRC 0.1 (-0.47,0.26) 0.53 (0.49,0.57) 0.41 (0.19,0.22) 0.41 
HADS 0.89 (-1.18,2.95) 3.68 (3.37,4.06) 2.44 (1.12,1.35) 2.44 
K-BILD 4.1 (-0.50,8.69) 7.01 (6.23,7.95) 6.25 (2.78,3.55) 6.25 
UCSD 9.55 (2.97,16.14) 14.19 (13.1,15.53) 4.14 (3.82,4.53) 9.55 
SGRQ-I 4.31 (-4.57, 13.18) 11.24 (10.57,12.06) 8.88 (4.18,4.76) 8.88 
 
Minimal clinically important difference using anchor and distribution methods for EQ-5D-5L: EQ-5D: 
EuroQol 5 Dimension, FVC: forced vital capacity, HADS: Hospital anxiety and depression scale, K-BILD: 
King’s brief interstitial lung disease questionnaire, mMRC: Medical Research Council dyspnea score, 
SGRQ: St George’s Respiratory Questionnaire, SGRQ-I, St George’s Respiratory Questionnaire – 
Interstitial lung disease, UCSD: University of California, San Diego shortness of breath questionnaire. SD: 






Patient Global Impression of Change (PGIC) questionnaire 
Since your last clinic visit, has there been any change in overall 
quality of life (satisfaction or happiness with life) related to 
your lung condition idiopathic pulmonary fibrosis, IPF? 
 
Please place a cross in the appropriate box. 
 
 A very great deal worse 
 A great deal worse 
 A good deal worse 
 Moderately worse 
 Somewhat worse 
 A little worse 
 Almost the same, hardly any worse at all 
 No change 
 Almost the same, hardly any better 
 A little better 
 Somewhat better 
 Moderately better 
 A good deal better 
 A great deal better 
 A very great deal better 
 
 
